Welcome to our dedicated page for Atara Biotherapeutics news (Ticker: ATRA), a resource for investors and traders seeking the latest updates and insights on Atara Biotherapeutics stock.
Atara Biotherapeutics, Inc. develops allogeneic T-cell immunotherapies through an Epstein-Barr virus (EBV) T-cell platform for cancer and autoimmune disease programs. Company news centers on tabelecleucel, also referred to as tab-cel or EBVALLO, regulatory communications with the FDA, and collaboration activity with Pierre Fabre Pharmaceuticals for the EBV-positive post-transplant lymphoproliferative disease program.
Recurring updates also cover financial results, commercialization revenue, research and development spending, operational efficiency measures, milestone and royalty-related agreements, and equity-linked financing instruments such as warrants. Atara also reports on its inventory-based cell therapy approach, platform attributes that avoid T-cell receptor or HLA gene editing, and pipeline candidates including ATA3431 and ATA3219.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, has announced that it will release its first quarter 2023 financial results after market close on Monday, May 8, 2023. The company specializes in developing transformative therapies for patients with cancer and autoimmune diseases, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform.